Short-course fluoroquinolones in acute exacerbations of chronic bronchitis

References

• Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med.106, 196–204 (1987).
   PubMed Web of Science ®Google Scholar
• Halpern MT, Higashi MK, Bakst AW, Schmier JK. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review. J. Manag. Care Pharm.9, 353–359 (2003).
   PubMedGoogle Scholar
• Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis: executive summary. Can. Respir. J.10, 248–258 (2003).
   PubMedGoogle Scholar
• Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J. Antimicrob. Chemother.43(Suppl. A), 97–105 (1999).
   PubMed Web of Science ®Google Scholar
• Brunton S, Carmichael BP, Colgan R et al. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. Am. J. Manag. Care10, 689–696 (2004).
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin. Ther.21, 576–591 (1999).
   PubMed Web of Science ®Google Scholar
• El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax63, 415–422 (2008).
   PubMedGoogle Scholar
• Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest117(5 Suppl. 2), 380S–385S (2000).
   Google Scholar
• Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest108(2 Suppl.), 43S–52S (1995).
   PubMed Web of Science ®Google Scholar
• Blasi F, Ewig S, Torres A, Huchon G. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. Pulm. Pharmacol. Ther.19, 361–369 (2006).
   PubMed Web of Science ®Google Scholar
• Niewoehner DE. Interventions to prevent chronic obstructive pulmonary disease exacerbations. Am. J. Med.117(Suppl. 12A), 41S–48S (2004).
   Google Scholar
• Martinez FJ. Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc.4, 647–658 (2007).
   PubMedGoogle Scholar
• Dever LL, Shashikumar K, Johanson WG Jr. Antibiotics in the treatment of acute exacerbations of chronic bronchitis. Expert Opin Investig. Drugs11, 911–925 (2002).
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis.32(Suppl. 2), S81–S93 (2001).
   PubMed Web of Science ®Google Scholar
• Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med.134, 595–599 (2001).
   PubMed Web of Science ®Google Scholar
• Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA273, 957–960 (1995).
   PubMed Web of Science ®Google Scholar
• Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest117, 1345–1352 (2000).
   PubMed Web of Science ®Google Scholar
• Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2, CD004403 (2006).
   Google Scholar
• O’Donnell DE, Aaron S, Bourbeau J et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. Can. Respir. J.14(Suppl. B), 5B–32B (2007).
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J.26, 1138–1180 (2005).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Monso E, Mesa J et al. Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement. Arch. Bronconeumol.44, 100–108 (2008).
   PubMedGoogle Scholar
• Miravitlles M, Zalacain R, Murio C et al. Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials: results of a two-year study. Clin. Drug Investig.23, 439–450 (2003).
   PubMed Web of Science ®Google Scholar
• Li-McLeod J, Perfetto EM. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag. Care Interface14, 52–59 (2001).
   PubMedGoogle Scholar
• Gotfried MH, DeAbate CA, Fogarty C, Mathew CP, Sokol WN. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin. Ther.23, 97–107 (2001).
   PubMed Web of Science ®Google Scholar
• Gotfried M, Notario G, Spiller J, Palmer R, Busman T. Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Curr. Med. Res. Opin21, 245–254 (2005).
   PubMed Web of Science ®Google Scholar
• Grossman RF, Ambrusz ME, Fisher AC, Khashab MM, Kahn JB. Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. Clin. Ther.28, 1175–1180 (2006).
   PubMed Web of Science ®Google Scholar
• Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J. Int. Med. Res.29, 314–328 (2001).
   PubMed Web of Science ®Google Scholar
• Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int. J. Antimicrob. Agents23, 129–137 (2004).
   PubMed Web of Science ®Google Scholar
• DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir. Med.94, 1029–1037 (2000).
   PubMed Web of Science ®Google Scholar
• Grassi C, Casali L, Curti E, Tellarini M, Lazzaro C, Schito G. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J. Chemother.14, 597–608 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson R, Kubin R, Ballin I et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother.44, 501–513 (1999).
   PubMed Web of Science ®Google Scholar
• Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest125, 953–964 (2004).
   PubMed Web of Science ®Google Scholar
• Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int. J. Antimicrob. Agents29, 56–61 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson R, Langan C, Ball P, Bateman K, Pypstra R. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir. Med.97, 242–249 (2003).
   PubMed Web of Science ®Google Scholar
• File T, Schlemmer B, Garau J, Lode H, Lynch S, Young C. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group. J. Chemother.12, 314–325 (2000).
   PubMed Web of Science ®Google Scholar
• Blasi F, Tarsia P, Aliberti S, Santus P, Allegra L. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm. Pharmacol. Ther.19(Suppl. 1), 11–19 (2006).
   PubMed Web of Science ®Google Scholar
• Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int. J. Antimicrob. Agents18, 503–512 (2001).
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Grossman RF, Zadeikis N et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur. Respir. J.25, 1001–1010 (2005).
   PubMed Web of Science ®Google Scholar
• Chodosh S, DeAbate CA, Haverstock D, Aneiro L, Church D. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir. Med.94, 18–27 (2000).
   PubMed Web of Science ®Google Scholar
• Urueta-Robledo J, Ariza H, Jardim JR et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respir. Med.100, 1504–1511 (2006).
   PubMed Web of Science ®Google Scholar
• Wilson R, Jones P, Schaberg T, Arvis P, Duprat-Lomon I, Sagnier PP. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax61, 337–342 (2006).
   PubMed Web of Science ®Google Scholar
• Sethi S, Fogarty C, Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir. Med.98, 697–707 (2004).
   PubMed Web of Science ®Google Scholar
• Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin. Ther.24, 639–652 (2002).
   PubMed Web of Science ®Google Scholar
• Ball P, Wilson R, Mandell L, Brown J, Henkel T. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin. J. Chemother.13, 288–298 (2001).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ros F, Cobos A, Kubin R, Tillotson G. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience. Int. J. Clin. Pract.55, 437–441 (2001).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Llor C, Naberan K, Cots JM, Molina J. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir. Med.99, 955–965 (2005).
   PubMed Web of Science ®Google Scholar
• Schaberg T, Moller M, File T, Stauch K, Landen H. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice. Clin. Drug Investig.26, 733–744 (2006).
   PubMed Web of Science ®Google Scholar
• Lorenz J, Thate-Waschke IM, Mast O et al. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J. Int. Med. Res.29, 74–86 (2001).
   PubMed Web of Science ®Google Scholar
• Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax58, 589–593 (2003).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Avgeri SG, Matthaiou DK, Dimopoulos G, Siempos II. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J. Antimicrob. Chemother.62, 442–450 (2008).
   PubMed Web of Science ®Google Scholar
• Wilson R. Short course of antibiotic treatment in acute exacerbations of COPD. Thorax63, 390–392 (2008).
   PubMedGoogle Scholar
• Mensa J, Trilla A. Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones. Clin. Microbiol. Infect.12(Suppl. 3), 42–54 (2006).
   PubMedGoogle Scholar